Miguel, J. et al. 2020. Cost-effectiveness of erlotinib compared to gefitinib for NSCLC with EGFR mutations at the Inca. Jornal Brasileiro de Economia da Saúde. 12, 1 (Apr. 2020), 8–15. DOI:https://doi.org/10.21115/JBES.v12.n1.p8-15.